---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-230984"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2025-10-06T23:59:59+00:00"
generated_at: "2026-05-17T04:36:36.883436+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Phathom Pharmaceuticals appoints Sanjeev Narula as CFO and Business Officer effective Oct 6, 2025

## Summary
- Sanjeev Narula named Chief Financial and Business Officer; replaces Robert Breedlove as principal financial officer.
- Initial base salary of $550,000 with annual target bonus of 50% of base salary.
- Receives stock options for 200,000 shares (4-year vest) and 144,000 RSUs (3-year annual vest).
- Narula previously CFO of Intra-Cellular Therapies and Viatris; brings extensive biopharma finance experience.
- Robert Breedlove continues as Vice President, Finance and principal accounting officer.

## SEC filing metadata
- accession: 0001193125-25-230984
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2025-10-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312525230984/0001193125-25-230984-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312525230984/d76139d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-230984
- JSON: https://secwatch.observer/filing/0001193125-25-230984.json
- Plain text: https://secwatch.observer/filing/0001193125-25-230984.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.